A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study.

ABSTRACT:

Background

Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma.

Methods

We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7 and a smoking history of >10 pack-years. Physicians selected biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) based on each United States Food & Drug Administration (FDA) approval criteria.

Results

After six-month treatment with biologics, both patien

SUBMITTER: Shim JS 

PROVIDER: S-EPMC10716772 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature